Bartlett & CO. Wealth Management LLC Trims Position in Zoetis Inc. (NYSE:ZTS)

Bartlett & CO. Wealth Management LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 6.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 306,590 shares of the company’s stock after selling 22,776 shares during the period. Bartlett & CO. Wealth Management LLC owned about 0.07% of Zoetis worth $49,953,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ZTS. Darwin Wealth Management LLC bought a new position in Zoetis in the third quarter worth approximately $31,000. First Personal Financial Services purchased a new stake in shares of Zoetis in the 3rd quarter worth $33,000. Capital Performance Advisors LLP bought a new position in Zoetis in the 3rd quarter worth $33,000. Dunhill Financial LLC lifted its position in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Quarry LP grew its holdings in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

ZTS opened at $166.64 on Thursday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a market capitalization of $75.18 billion, a price-to-earnings ratio of 31.32, a PEG ratio of 2.58 and a beta of 0.89. The company has a fifty day moving average of $170.60 and a 200 day moving average of $179.89. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same quarter last year, the business posted $1.36 earnings per share. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. This is a boost from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s dividend payout ratio is 37.59%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ZTS. Leerink Partners began coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. JPMorgan Chase & Co. upped their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and a consensus price target of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.